These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25511521)

  • 61. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
    Brannan T; Prikhojan A; Yahr MD
    J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease.
    Gallagher CL; Johnson SC; Bendlin BB; Chung MK; Holden JE; Oakes TR; Brooks BR; Konopacki RA; Dogan S; Abbs JH; Xu G; Nickles RJ; Pyzalski RW; Dejesus OT; Brown WD
    Brain Imaging Behav; 2011 Sep; 5(3):203-11. PubMed ID: 21556744
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
    Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
    J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase.
    Törnwall M; Tuomainen P; Männistö PT
    Eur J Pharmacol; 1993 Aug; 239(1-3):39-45. PubMed ID: 8223912
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-L-dopa in rhesus monkey.
    Günther I; Psylla M; Reddy GN; Antonini A; Vontobel P; Reist HW; Zollinger A; Nickles RJ; Beer HF; Schubiger PA
    Nucl Med Biol; 1995 Oct; 22(7):921-7. PubMed ID: 8547890
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism.
    Giakoumaki SG; Roussos P; Bitsios P
    Neuropsychopharmacology; 2008 Dec; 33(13):3058-68. PubMed ID: 18536698
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects.
    Dingemanse J; Jorga K; Zürcher G; Fotteler B; Sedek G; Nielsen T; van Brummelen P
    Eur J Clin Pharmacol; 1996; 50(1-2):47-55. PubMed ID: 8739811
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Catechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors.
    Männistö PT
    Adv Pharmacol; 1998; 42():324-8. PubMed ID: 9327906
    [No Abstract]   [Full Text] [Related]  

  • 70. Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline.
    Davis TL; Roznoski M; Burns RS
    Clin Neuropharmacol; 1995 Aug; 18(4):333-7. PubMed ID: 8665546
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
    Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
    Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease.
    Hanson MR; Gálvez-Jiménez N
    Semin Neurol; 2001; 21(1):15-22. PubMed ID: 11346021
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers.
    Jorga KM
    Neurology; 1998 May; 50(5 Suppl 5):S31-8. PubMed ID: 9591520
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tolcapone: a novel approach to Parkinson's disease.
    Micek ST; Ernst ME
    Am J Health Syst Pharm; 1999 Nov; 56(21):2195-205. PubMed ID: 10565698
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
    Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
    Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Microdialysis study of tolcapone effect during blockage of neuronal dopamine reuptake caused by GBR-12909].
    Budygin EA; Gaĭnetdinov RR; Raevskiĭ KS; Li IH; Mannisto PT
    Eksp Klin Farmakol; 1997; 60(5):8-10. PubMed ID: 9483396
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma.
    Maser T; Rich M; Hayes D; Zhao P; Nagulapally AB; Bond J; Saulnier Sholler G
    Cancer Med; 2017 Jun; 6(6):1341-1352. PubMed ID: 28429453
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease.
    Cheesman AL; Barker RA; Lewis SJ; Robbins TW; Owen AM; Brooks DJ
    J Neurol Neurosurg Psychiatry; 2005 Sep; 76(9):1204-10. PubMed ID: 16107352
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Insight into the Therapeutic Potential of a Bicyclic Hydroxypyridone Compound 2-[(2,4-Dichlorophenyl)methyl]-7-hydroxy-1,2,3,4-tetrahydro-8H-pyrido[1,2-a]pyrazin-8-one as COMT Inhibitor in the Treatment of Parkinson's Disease: A Molecular Dynamic Simulation Approach.
    Subair TI; Akawa OB; Soremekun OS; Olotu FA; Soliman MES
    Chem Biodivers; 2021 Sep; 18(9):e2100204. PubMed ID: 34252268
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Improved functional and histochemical outcomes in l-DOPA plus tolcapone treated VMAT2-deficient mice.
    Moreira CG; Morawska MM; Baumann A; Masneuf S; Linnebank M; Sommerauer M; Landolt HP; Noain D; Baumann CR
    Neuropharmacology; 2020 Dec; 181():108353. PubMed ID: 33038358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.